Specialty Pharmacy Integration of Oral Fecal Microbiota Spores Enables Medication Access in Over Half of Patients with Recurrent C difficile Infection Quality improvement initiative at Henry Ford Health demonstrates streamlined workflow, rapid prior authorization, and low patient copayments; highlights opportunities for enhanced pharmacist involveme...

Another study from #MADID2025 highlighting specialty pharmacy integration of oral fecal microbiota spores enabled access in over 50% of patients with recurrent C difficile infection. #IDsky #MEDsky #rCDI

Read more: www.contagionlive.com/view/special...

Real-World Use of Fecal Microbiota, live-jslm Shows High Success in Preventing Recurrent C difficile Infection A multicenter US study confirms that RBL is a safe and effective microbiota-based therapy with sustained remission in a high-risk, comorbid population.

#MADID2025: Real-world data confirms the power of microbiota-based therapy. Fecal Microbiota, live-jslm (RBL) achieved 77.6% success at 8 weeks and 87% sustained remission at 6 months in high-risk, elderly patients w/ recurrent CDI #IDsky #MEDsky

Read more: www.contagionlive.com/view/real-wo...

Impact of Obesity on Micafungin Treatment Outcomes in Candidemia A retrospective study finds no significant difference in treatment failure between obese and non-obese patients.

A study presented at #MADID2025 found that obesity did not increase the risk of treatment failure in candidemia patients treated with standard-dose micafungin. Hemodialysis raised risk, but longer antifungal therapy was protective. #IDsky #MEDsky

Read more: www.contagionlive.com/view/impact-...

Pharmacist-Led Review Uncovers Frequent ART Errors in Hospitalized Adults With HIV More than 80% of patients had drug-related problems, highlighting the need for inpatient antiretroviral stewardship.

Study from #MADID2025 study found 80% of hospitalized adults with HIV had ART-related issues, mostly drug interactions and dosing errors. Pharmacist-led interventions fixed all problems within 24 hours. #IDsky #MEDsky #HIVsky

Read more: www.contagionlive.com/view/pharmac...

Ceftolozane/Tazobactam Shows Strong Activity Against ESBL E coli, But Gaps Remain for K pneumoniae At MAD-ID, Jose Alexander, MD, reports 98% susceptibility in ESBL E coli and 76% in K pneumoniae, underscoring the need for species-specific testing.

❗ ICYMI: In vitro results show ceftolozane/tazobactam is 98% effective against ESBL-producing E. coli, but less promising for Klebsiella pneumonia. #IDsky #MEDsky

Dr. Jose Alexander presented findings at #MADID2025

Listen here: www.contagionlive.com/view/ceftolo...

MAD-ID 2025 Highlights Fidaxomicin’s Role in Reducing C difficile Recurrence Multiple studies highlight fidaxomicin’s effectiveness across high-risk populations despite cost and access challenges, underscoring the need for education and stewardship to improve guideline adheren...

At #MADID2025, a clear theme emerged, highlighting fidaxomicin as the preferred treatment for C. difficile infection in patients at risk of recurrence. @mad-id.bsky.social #IDsky #MEDsky #Cdiffsky

Read all about it: www.contagionlive.com/view/mad-id-...

Fidaxomicin Tied to Lower C difficile Recurrence in Immunocompromised Patients Presented at MAD-ID 2025, Natt Patimavirujh, PharmD, supports fidaxomicin over vancomycin for high-risk groups, including transplant and chemotherapy patients.

At #MADID2025, Natt Patimavirujh presented data showing fidaxomicin reduced C diff recurrence to 5% vs 30% with vancomycin in immunocompromised patients, including those undergoing transplant or chemotherapy. @mad-id.bsky.social #IDsky #MEDsky

Listen here: www.contagionlive.com/view/fidaxom...

Impact of Obesity on Antibiotic Treatment Outcomes Presented at MAD-ID by Mohammed Al Musawi, PharmD, BCIDP, the study found lower clinical success with imipenem-cilastatin-relebactam in obese patients, raising questions about dosing strategies.

🎥 At #MADID2025, Dr. Mohammed Al Musawa presented a multicenter analysis finding that obese patients treated with imipenem-cilastatin-relebactam had a lower clinical success rate compared to non-obese patients. @mad-id.bsky.social #IDsky #MEDsky

Listen here: www.contagionlive.com/view/impact-...

Fidaxomicin Reduces Recurrence Risk in High-Risk C difficile Infections At MAD-ID, Alyssa Cox, PharmD, showed fidaxomicin reduces 90-day recurrence by 68.3% versus vancomycin, with rates of 7.9% vs. 19% in 176 hospitalized patients.

At #MADID2025, Dr. Alyssa Cox, PharmD, presented data showing fidaxomicin reduced 90-day C difficile recurrence rates to 7.9% vs. 19% with vancomycin, a 68.3% lower risk in high-risk hospitalized patients. @mad-id.bsky.social #IDsky #MEDsky

Listen here: www.contagionlive.com/view/fidaxom...

Ceftolozane/Tazobactam Shows Strong Activity Against ESBL E coli, But Gaps Remain for K pneumoniae At MAD-ID, Jose Alexander, MD, reports 98% susceptibility in ESBL E coli and 76% in K pneumoniae, underscoring the need for species-specific testing.

🎥 At #MADID2025, Dr. Jose Alexander from @adventhealth.bsky.social in Orlando, discussed data that ceftolozane/tazobactam showed 98% susceptibility against ESBL E. coli but only 76% for K. pneumoniae. @mad-id.bsky.social #IDsky #MEDsky

Full interview: www.contagionlive.com/view/ceftolo...

Vancomycin Loading Doses Improve Target Timing and Safety in 61,000+ Cases At MAD-ID 2025, Tiffany Lee, PharmD, presents multi-center findings showing no increase in AKI with higher initial dosing.

At #MADID2025, Dr. Tiffany Lee from InsightRX, presented a multi-center study showing that vancomycin loading doses significantly improve AUC target timing without increasing AKI risk. @mad-id.bsky.social #IDsky #MEDsky

Listen to our full interview here: www.contagionlive.com/view/vancomy...

No Significant Difference Between Doxycycline and Minocycline for Bone and Joint Infections At MADID 2025, William R Mikesell, PharmD, presented data showing 20% vs 16% treatment failure rates in doxycycline and minocycline groups.

🎥 At #MADID2025, Dr. William Mikesell from IU Health shared findings showing no significant difference in treatment failure between doxycycline (20%) and minocycline (16%) for bone & joint infections. @mad-id.bsky.social #IDsky #MEDsky

Listen here: www.contagionlive.com/view/no-sign...

Immunocompromised Patients on OPAT Face Nearly Double the Risk of 30-Day Readmission Christina Lee, PharmD, and Julia Donahue, PharmD, analyzed 533 encounters revealing a 27.1% readmission rate in immunocompromised patients versus 14.1% in non-immunocompromised patients.

At #MADID2025, Dr's. Julia F. & Christina Lee from UNC Medical Center presented that immunocompromised patients on OPAT had a 27.1% 30-day readmission rate compared to 14.1% in non-immunocompromised patients. @mad-id.bsky.social #IDsky #MEDsky

Listen here: www.contagionlive.com/view/immunoc...

VOWST Maintains Consistent Safety Profile in rCDI Patients with Comorbidities At MAD-ID, Dianne Nguyen, MD, shares Phase 3 data showing consistent tolerability of the microbiome therapy across high-risk patient populations

🎥 At #MADID2025, Dr. Dianne Nguyen, Head of Medical Affairs for the Pharmaceutical Division at Nestlé Health Science, presented Phase 3 data showing VOWST is well-tolerated in adults w/ recurrent C diff infection. @mad-id.bsky.social #IDsky #MEDsky

Listen: www.contagionlive.com/view/vowst-s...

Reviewing the Efficacy and Safety of Omadacycline in Immunocompromised Patients In a new study presented at MAD-ID, omadacycline was found to have an 86% clinical success rate across a wide-range of infections and pathogens in an immunocompromised population.

In a new study presented at #MADID2025, omadacycline was found to have an 86% clinical success rate across a wide-range of infections and pathogens in an immunocompromised population. #IDsky #Medsky

Stay tuned for our interview with Dr. Dianne Nguyen from Nestlé Health Science as she breaks down new #MADID2025 data on VOWST. @mad-id.bsky.social #IDsky #MEDsky

www.contagionlive.com/conference/m...

Precision in Practice: PK/PD Modeling Advances Infectious Disease Care At MAD-ID, Mark Sheets, PharmD, discusses how PK/PD modeling and AUC-based strategies offer safer, more precise antibiotic therapy.

🎥 At #MADID2025, Dr. Marc Scheetz, from Midwestern University, shares how PK/PD modeling and AUC-based dosing are helping clinicians make safer, more personalized antibiotic decisions—right at the bedside. @mad-id.bsky.social #IDsky #MEDsky #AMRsky

Listen here: www.contagionlive.com/view/precisi...

Rethinking Fungal Blood Cultures in Sepsis Workups Logan Brock, PharmD, presents data at MAD-ID 2025, showing limited diagnostic yield from routine fungal cultures and delayed results compared to standard methods.

At #MADID2025, Dr. Logan Brock presented that routine fungal blood cultures during sepsis evaluations may offer limited diagnostic value; a more targeted approach may be appropriate. #IDsky #MEDsky @mad-id.bsky.social

Listen here: www.contagionlive.com/view/rethink...

Gram-positive bloodstream
Infections

#MADID2025

@erinmccreary.bsky.social @mad-id.bsky.social

#MADID2025 has wrapped up in Orlando, but we’re continuing our coverage. Look out for new interviews, research highlights, & expert insights all week! @mad-id.bsky.social #IDsky #MEDsky

🎥 Stay tuned for Dr. Tiffany Lee's interview this week!

Coverage: www.contagionlive.com/conference/m...

Another great talk from #MADID2025 : Advances in Diagnostic and Laboratory
Science with @romneyintn.bsky.social

#microbiology @mad-id.bsky.social

Wrapping up our final day at #MADID2025 in Orlando! 🦠 💊 @mad-id.bsky.social #IDsky #MEDsky

It was great to learn from & discuss the posters and presentations showcasing important work in infectious diseases & stewardship. Until next year!

Conference coverage: www.contagionlive.com/conference/m...

Oral Vancomycin "Tail" Offers No Added Benefit for CDI Prophylaxis At MAD-ID 2025, Jiye Park, PharmD, presents findings showing once-daily dosing is effective, with no added benefit from extended vancomycin use after antibiotics.

🎥 At #MADID2025, Dr. Jiye Park from Massachusetts General Hospital shared data showing no added benefit from extending oral vancomycin after systemic antibiotics for CDI prophylaxis. @mad-id.bsky.social #IDsky #MEDsky

Listen to more of the results here: www.contagionlive.com/view/oral-va...

Finishing our final day of #MADID2025 with the acclaimed "What did you miss in ID"

Drs. Zahra Kassamali Escobar and Jamie Wagner will catch us up on critical publications from 2024-2025! 🤓

@sidpharm.bsky.social @accpinfdprn.bsky.social @contagionlive.bsky.social

Starting our 🔥 final day of #MADID2025 with Armando Nahum and Dr. Marin Schweizer speaking on the importance of the ♥️ patient experience and 😷 infection prevention.

@sidpharm.bsky.social @accpinfdprn.bsky.social @contagionlive.bsky.social

Closing out Day 3️⃣ of #MADID2025, Drs. Zahra Kassamali-Escobar and Erin McCreary discuss the Gray in "Gray-M" Positive 🟣 Infections: ⏬ Step Down Therapy - Focus on 💊 Oral and Long Acting 💉 IV Antibiotics!

@sidpharm.bsky.social @accpinfdprn.bsky.social @contagionlive.bsky.social

Fidaxomicin Use Remains Flat Despite Guideline Change for C difficile Treatment At MAD-ID 2025, Dakota Rorie, PharmD, highlights cost and access barriers to uptake of preferred CDI therapy.

At #MADID2025, Dakota Rorie, PharmD from Medical University of South Carolina, found fidaxomicin use for C. difficile stayed nearly flat post-guideline update, 48% to 49% for initial episodes. @mad-id.bsky.social #IDsky #MEDsky

Listen to our interview here: www.contagionlive.com/view/fidaxom...

Next up at #MADID2025, Drs. Cesar Arias and Jason Pogue discuss 🦠 Challenging Gram ➕ and Gram ➖ Organisms

@sidpharm.bsky.social @accpinfdprn.bsky.social @contagionlive.bsky.social

More of #MADID2025

My favorite talk so far. New developments in antibacterial drugs : sulopenen, aztreonam-avibactam, and more.

@ashlan-kunz-coyne.bsky.social
@mad-id.bsky.social

💡Great afternoon of interviews with insightful takeaways on improving patient care and implementing guidelines! 🦠💊 #MADID2025 @mad-id.bsky.social #IDsky #MEDsky #AMRsky

Stay updated with onsite coverage here: www.contagionlive.com/conference/m...